EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

Conditions:   Ovarian Carcinosarcoma;   Uterine Carcinosarcoma Interventions:   Drug: Eribulin Mesylate;   Drug: Pembrolizumab Sponsors:   Australia New Zealand Gynaecological Oncology Group;   Eisai Inc.;   Merck Sharp & Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials